CHICAGO, IL -- February 26, 2007 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, launched a new, automated viscometer for high-volume used oil analysis laboratories at PITTCON® 2007, Booth 843, further broadening PerkinElmer’s range of offerings for used oil analysis.  The qVisc 4320 AX Autosampler Viscometer is designed to help increase throughput and work seamlessly with other used oil analysis instrumentation. 

“This analyzer with fully integrated autosampler can run an unprecedented 200 samples unattended to dramatically increase laboratories’ throughput,” said Michael DiVito, Thermal and Elemental Analysis business unit manager, PerkinElmer Life and Analytical Sciences.  “Customers have the added peace-of-mind that the viscometer comes with PerkinElmer’s global network of service to help support their research and testing.”

The measurement of viscosity is typically the first analysis made by a used oil laboratory.  From the viscosity value, the laboratory can identify different chemical levels in the oil and quickly determine if a potential problem exists with the sample.  If a problem is detected, further analysis of the sample can readily be made, using other instrumentation to determine the root cause of the problem.

The viscometer adheres to ASTM method D445, the common industry standard for analyzing oil, which requires that the oil flow under gravity through a glass capillary tube held at a constant temperature in a bath.  In addition, this advanced system automatically adds solvents as needed and maintains the cleanliness of the glassware to reduce operator intervention and increase uptime.   

“The viscometer ensures high sample throughput even when contaminants build up on the inside of the tube,” said DiVito. “It constantly measures potential buildup of soot, suspended solids, oxidation and nitration products and other compounds.  It also alerts the operator when buildups are present and automatically takes a problem tube offline while redirecting samples to tubes that are not experiencing buildup, saving valuable time.”

Samples are analyzed as rapidly as up to 64 per hour at a single temperature and up to 47 samples per hour using two temperatures.  During the analysis, the system’s software performs quality control checks and monitors all critical functions.  For laboratories with a lighter sampling load, the model HSV 802 Viscometer provides a high level of performance without the autosampler capability.

PerkinElmer is marketing, selling and servicing Fluid Life kinematics viscometers, including the qVisc 4320 AX Autosampler Viscometer, under a distribution agreement with Fluid Life Corp.

Other PerkinElmer instrumentation that is used in used oil analysis include Fourier Transform Infrared (FT-IR) instruments for testing oil contamination and the durability of oil, gas chromatography instruments for testing oil dilution and leak detection, and Inductively Coupled Plasma (ICP) instruments for testing metals in oil and determining how oil was formulated.

For more information on the qVisc 4320 AX Autosampler Viscometer or HSV 802 Viscometer, visit www.perkinelmer.com/viscosity.

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements.  Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct.  A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements.  These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging.  Photonics markets include sensors and specialty lighting.